David Broughton

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Martin Dennis, Gillian Mead, John Forbes et al. · The Lancet · 2018 · 286 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial

Yining Huang, Richard I. Lindley, Xiaoying Chen et al. · The Lancet · 2019 · 271 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Rustam Al‐Shahi Salman, M. J. S. Dennis, PAG Sandercock et al. · The Lancet · 2019 · 195 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial

Philip M. Bath, Lisa J Woodhouse, Jason P. Appleton et al. · The Lancet · 2017 · 180 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Smoking cessation and outcome after ischemic stroke or TIA

Katherine A. Epstein, Catherine M. Viscoli, J. David Spence et al. · Neurology · 2017 · 94 citations · Full text

Public Health, Cardiology, Pharmacotherapy +17